trump glp 1 deal The administration announced deals that will lower the prices of major obesity drugs for many Americans. Under the deals with Eli Lilly and Novo Nordisk, those buying injectable GLP-1 Novo Nordisk, Lilly strike deal

Agents that agonize glucagon-like peptide 1 receptors, including those that co-agonize other anorexigenic hormone receptors, lead to substantial weight loss and benefits in people with varying obesity-related complications, with further trials underway

Today, I spoke live with Paul Bagnell, news anchor with Bloomberg BNN, on the topic of the GLP-1 agonists and their impact on health care, industries beyond health and medicine, and consumers

Discover how the GLP-1 revolution with Ozempic and Mounjaro is transforming Type 2 diabetes and obesity treatment, offering new hope and solutions.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, today announced that they have entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist